
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is well positioned in the life sciences tools and diagnostics industry, with a strong presence in both the protein sciences and diagnostic and genomics segments. The company's global operations and diverse product portfolio make it attractive to a wide range of customers and markets. Additionally, Bio-Techne's recent acquisition of Wilson Wolf is expected to further enhance its standing in the industry and contribute to future growth. The company's strong focus on sustainability and corporate governance also speaks to its commitment to long-term success. Overall, we believe Bio-Techne has solid fundamental reasons for continued growth and success in the future, making it an attractive investment opportunity.
Bears say
Bio-Techne is facing headwinds in the near-term due to challenges in the cell therapy market and a delay in demand pick-up, but the company has implemented self-help initiatives to improve its overall business. Additionally, the recent acquisition of Wilson Wolf, which gives Bio-Techne a strong presence in the growing cell therapy market, is a positive move for the company's long-term growth prospects. While Bio-Techne may be facing some competitive pressures in certain markets, the overall industry outlook remains strong, with continued investments from large pharmaceutical companies and positive signals from the biotech sector.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares